In This Section |
This section contains the following topics:
|
1. Female Sexual Arousal Disorder (FSAD)
Introduction |
This topic contains information about evaluating FSAD, including |
Change Date |
May 19, 2020 |
V.iii.8.A.1.b. Requesting Examinations for FSAD Claims |
The Gynecological Conditions Disability Benefits Questionnaire (DBQ) is the appropriate DBQ to order when a Department of Veterans Affairs examination is necessary to assist in substantiating a claim of FSAD or other female sexual dysfunction.
Notes:
|
V.iii.8.A.1.c. Within Scope Determinations for FSAD |
If SC for FSAD is not expressly claimed, consider FSAD within scope of the claim in the circumstances described in the table below.
|
V.iii.8.A.1.d. Evaluating FSAD |
When the requirements are met, SC for FSAD will be awarded as a stand-alone gynecological disability using 38 CFR 4.116, diagnostic code (DC) 7632 with a 0-percent evaluation. This is the maximum evaluation available for FSAD.
Note: The original clarification that FSAD is a disorder subject to SC was not a regulatory change. Consequently, the provisions of 38 CFR 3.114 do not apply for assignment of the effective date. Subsequent updates to 38 CFR 4.116, including the addition of DC 7632 for FSAD, effective May 13, 2018, are, similarly, not liberalizing. |
2. Other Gynecological Disorders
Introduction |
This topic contains information about evaluating other gynecological disorders, including
|
Change Date |
November 8, 2021 |
V.iii.8.A.2.a. SC for Disorders of Menstruation |
A disease or injury resulting in ovarian dysfunction affecting the menstrual cycle, such as dysmenorrhea and secondary amenorrhea, can be service-connected (SC). Evaluate using 38 CFR 4.116, DC 7615.
Notes:
|
V.iii.8.A.2.b. Evaluating Pelvic Organ Prolapse |
Apply the principles below to evaluate pelvic organ prolapse.
Example: SC is warranted for pelvic organ prolapse. Examination shows that, as a result of complete prolapse, the Veteran also experiences urinary incontinence requiring the wearing of absorbent materials that must be changed twice daily, impairment of sphincter control resulting in slight leakage, and localized dermatitis affecting less than five percent of body area that is treated with topical therapy. The following evaluations will be established for the pelvic organ prolapse and residuals:
Note: Prior to the changes to 38 CFR 4.116, effective May 13, 2018, these conditions were evaluated under 38 CFR 4.116, DC 7621 to 7623.
References: For more information on
|
V.iii.8.A.2.c. Malignant Neoplasms of the Gynecological System |
Separate 100-percent evaluations will be assigned for both active gynecological cancer and active breast cancer. Metastasis of a gynecological cancer or breast cancer to a different body system will also be evaluated separately.
Consider corresponding entitlement to SMC.
References: For more information on
|
V.iii.8.A.2.d. Disfigurement Due to Benign or Malignant Neoplasms |
Do not evaluate disfigurement due to benign or malignant neoplasms of the gynecological system analogous to 38 CFR 4.118, DC 7800. DC 7800 is for evaluation of disfigurement of the head, face, or neck only. |
V.iii.8.A.2.f. HPV |
- genital warts that are shown in service or by nexus to be associated with the HPV infection, and
- HPV resulting in persistent infection that progresses to cervical dysplasia and subsequently to cervical cancer.
- 38 CFR 3.301(c)(1), and
V.iii.8.A.2.g. Changes in the Rating Schedule for Gynecological Conditions and Disorders of the Breast |
The rating criteria for gynecological conditions and disorders of the breast have undergone historical changes. Recent full-scale historical revisions were effective on the following dates:
Note: These changes in the rating criteria
|